Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avanos Medical (AVNS) Shares Outstanding (Weighted Average) (2016 - 2025)

Avanos Medical (AVNS) has disclosed Shares Outstanding (Weighted Average) for 13 consecutive years, with $46.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 0.65% to $46.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.3 million through Dec 2025, up 0.65% year-over-year, with the annual reading at $46.3 million for FY2025, 0.65% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $46.3 million in Q4 2025 for Avanos Medical, roughly flat from $46.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $48.1 million in Q2 2021 to a low of $46.0 million in Q3 2024.
  • Historically, Shares Outstanding (Weighted Average) has averaged $46.8 million across 5 years, with a median of $46.6 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): fell 3.12% in 2022 and later increased 0.87% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $48.1 million in 2021, then fell by 2.49% to $46.9 million in 2022, then decreased by 0.64% to $46.6 million in 2023, then dropped by 1.29% to $46.0 million in 2024, then grew by 0.65% to $46.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for AVNS at $46.3 million in Q4 2025, $46.4 million in Q3 2025, and $46.3 million in Q2 2025.